IMMIX Biopharma earnings were -$20.9M for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest IMMX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$4.5M, down 5.6% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, IMMX reported annual earnings of -$21.6M, with 40.1% growth.
What were IMMIX Biopharma's earnings last quarter?
On IMMX's earnings call on Invalid Date, IMMIX Biopharma (NASDAQ: IMMX) reported Q1 2025 earnings per share (EPS) of -$0.15, up 31.82% year over year. Total IMMX earnings for the quarter were -$4.54 million. In the same quarter last year, IMMIX Biopharma's earnings per share (EPS) was -$0.22.
As of the last IMMIX Biopharma earnings report, IMMIX Biopharma is currently losing money. IMMIX Biopharma's net profit (also called net income) for the twelve months ending Mar 31, 2025 was -$20.90 million, a 14.78% increase year over year.
What was IMMX's earnings growth in the past year?
As of IMMIX Biopharma's earnings date in Invalid Date, IMMIX Biopharma's earnings has grown year over year. IMMX earnings in the past year totalled -$20.90 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.